Author's response to reviews

Title: Significance of a Reduction in HCV RNA Levels at 4 and 12 Weeks in Patients Infected with HCV Genotype 1b for the Prediction of the Outcome of Combination Therapy with Peginterferon and Ribavirin

Authors:

Hidenori Toyoda (tkumada@he.mirai.ne.jp)
Takashi Kumada (hosp3@omh.ogaki.gifu.jp)
Noritomo Shimada (noritomos@jcom.home.ne.jp)
Koichi Takaguchi (k.takaguchi@chp-kagawa.jp)
Tatsuya Ide (ide@med.kurume-u.ac.jp)
Michio Sata (msata@med.kurume-u.ac.jp)
Hiroyuki Ginba (hiroyuki.ginba@roche.com)
Kazuhiro Matsuyama (kazuhiro.matsuyama@roche.com)
Namiki Izumi (nizumi@musashino.jrc.or.jp)

Version: 4 Date: 26 October 2012

Author's response to reviews: see over
October 26, 2012
The Editor,
BMC Infectious Diseases

Dear the Editor,
Please find the second revision of our manuscript entitled "Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin”.

Thank you very much for your suggestion for second revision. We corrected the points that you kindly suggested and deleted references 34 and 35. We are looking forward to the final decision.
Sincerely yours,

Hidenori Toyoda, M.D., Ph.D.
Department of Gastroenterology, Ogaki Municipal Hospital
4-86 Minaminokawa, Ogaki, 503-8502, Japan
Phone: (+81) 584-81-3341
Fax: (+81) 584-75-5715
E-Mail Address; tkumada@he.mirai.ne.jp

There is no grant support and other assistance, and there is no conflict of interest on this manuscript.